In prostate cancer, SNHG6 modulates cancer cell sensitivity to paclitaxel by sponging miR-186 [43], SNHG12 influences tumorigenesis through targeting miR-133b [122], and SNHG4 enhances ZIC5-mediated tumor growth and metastasis via the regulation of miR-377 [42]. Here, ZIC5 is linked to prostate cancer.